The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite ...
Novo Nordisk announced Monday that it is significantly cutting the prices of its blockbuster GLP-1 drugs, Wegovy (for weight ...
Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...
Major stock indexes ended sharply lower to begin the week, which will see AI darling Nvidia and retail giants report ...
Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals ...
Bitcoin just erased all of its gains for this year — and some analysts say more turbulence could be in store for the ...
By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...
Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback